[Quality improvement potential in the pharmaceutical industry].
The performance of the German pharmaceutical industry, future challenges and obstacles to quality improvement are assessed from a systems-of-innovation perspective, using appropriate innovation indicators. The current close-to-market performance indicators paint an unfavourable picture. Early R&D indicators (e.g., publications, patents), however, reveal a positive trend. A lot of obstacles to quality improvements are identified with respect to knowledge base, knowledge/technology transfer, industrial R&D processes, capital markets, market attractiveness and both regulatory and political framework conditions. On this basis, recommendations will finally be derived to improve quality in the pharmaceutical industry.
Nusser
Michael
M
Fraunhofer-Institut für System- und Innovationsforschung (ISI), Karlsruhe. michael.nusser@isi.fraunhofer.de
D002986:Clinical Trials as Topic / Q000592:standards; D004345:Drug Industry / Q000592:standards* / Q000639:trends; D005858:Germany; D006801:Humans; D011785:Quality Assurance, Health Care